AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19067776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention (3 sessions/4 weeks)
Number of subjects: 152
Study 19067776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 17254907 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal grip strength trials
Number of subjects: 30
Study 17254907 — intervention group
Group type: COMPARATOR
Intervention: Submaximal grip strength trials
Number of subjects: 30
Study 17254907 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope of the force‐generation phase
Number of subjects: 30
Study 17254907 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope of the force‐decay phase
Number of subjects: 30
Study 15146330 — intervention group
Group type: EXPERIMENTAL
Intervention: L -5-Hydroxytryptophan (2 mg/kg per day) administered at bedtime for 20 consecutive days
Number of subjects: 45
Study 15146330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study 11766248 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (various doses)
Number of subjects: 0
Study 11766248 — intervention group
Group type: COMPARATOR
Intervention: Omitting reversal of neuromuscular block
Number of subjects: 0
Study 11766248 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four ratio > or = 0.9
Number of subjects: 0
Study 9526930 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg plus ondansetron 4 mg
Number of subjects: 160
Study 9526930 — intervention group
Group type: COMPARATOR
Intervention: Droperidol plus saline (Control)
Number of subjects: 160
Study 7926977 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (r‐EPO) administered subcutaneously at dosages up to 1050 U/kg a week for at least two months
Number of subjects: 26
Study 7926977 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (r‐EPO)
Number of subjects: 26
Study 7926977 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (N=42)
Number of subjects: 26
Study 2512637 — intervention group
Group type: EXPERIMENTAL
Intervention: tenoxicam 20 mg daily
Number of subjects: 20
Study 2512637 — intervention group
Group type: COMPARATOR
Intervention: piroxicam 20 mg daily
Number of subjects: 20
Study 1105630 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital (100 mg)
Number of subjects: 1
Study 1105630 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital (130 mg)
Number of subjects: 1
Study 1105630 — intervention group
Group type: EXPERIMENTAL
Intervention: CPZ (0.667 and 1.334 mg/kg)
Number of subjects: 1
Study 1105630 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.071, 0.142, and 0.284 mg/kg)
Number of subjects: 1
Study 29479829 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoring writing task
Number of subjects: 271
Study 29479829 — intervention group
Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 271
Study 27109623 — intervention group
Group type: EXPERIMENTAL
Intervention: Verucerfont (350 mg per day)
Number of subjects: 39
Study 27109623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 24703529 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS 2mA
Number of subjects: 18
Study 24703529 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS 1mA
Number of subjects: 18
Study 24703529 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study 21994343 — intervention group
Group type: EXPERIMENTAL
Intervention: Active snus
Number of subjects: 250
Study 21994343 — intervention group
Group type: COMPARATOR
Intervention: Placebo snus
Number of subjects: 250
Study 20174998 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote electronic tool
Number of subjects: 135
Study 20174998 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face time trade-off
Number of subjects: 135
Study 18285429 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture
Number of subjects: 14
Study 18285429 — intervention group
Group type: COMPARATOR
Intervention: Chinese medical acupuncture
Number of subjects: 14
Study 16503881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 0
Study 16503881 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care with emollients and topical corticosteroids)
Number of subjects: 0
Study 12788302 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat fibrinolytic therapy
Number of subjects: 670
Study 12788302 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment (repeat fibrinolysis or urgent revascularization)
Number of subjects: 670
Study 12788302 — intervention group
Group type: EXPERIMENTAL
Intervention: Death within 24 h of reinfarction
Number of subjects: 670
Study 12788302 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year mortality
Number of subjects: 670
Study 11707834 — intervention group
Group type: COMPARATOR
Intervention: CHOP (3 courses)
Number of subjects: 58
Study 11707834 — intervention group
Group type: EXPERIMENTAL
Intervention: ESHAP followed by HDT and PBPCT
Number of subjects: 58
Study 11707834 — intervention group
Group type: EXPERIMENTAL
Intervention: ESHAP/HDT
Number of subjects: 58
Study 11707834 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 58
Study 8610234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin
Number of subjects: 612
Study 8610234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine plus cisplatin
Number of subjects: 612
Study 2058576 — intervention group
Group type: COMPARATOR
Intervention: 0% lactose milk
Number of subjects: 6
Study 2058576 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% lactose-reduced milk
Number of subjects: 6
Study 2058576 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% lactose-reduced milk (#1)
Number of subjects: 6
Study 2058576 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% lactose-reduced milk (#2)
Number of subjects: 6
Study 2058576 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% lactose-reduced milk
Number of subjects: 6
Study 6845046 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoylmetronidazole 50 ml (2 g metronidazole equivalent) as a single dose
Number of subjects: 0
Study 6845046 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Trichomonas vaginalis infection)
Number of subjects: 0
Study 6845046 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients free of Trichomonas vaginalis infection)
Number of subjects: 0
Study 30173286 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenterics intragastric balloon – Orbera + VLCKD (n = 40)
Number of subjects: 80
Study 30173286 — intervention group
Group type: COMPARATOR
Intervention: Orbera + LCD (n = 40)
Number of subjects: 80
Study 26892080 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stenting (n = 52)
Number of subjects: 105
Study 26892080 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) (n = 53)
Number of subjects: 105
Study 25315942 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (β-blocker)
Number of subjects: 41
Study 22755276 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma
Number of subjects: 44
Study 22755276 — intervention group
Group type: COMPARATOR
Intervention: Amantadine
Number of subjects: 44
Study 22755276 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma (relapsers)
Number of subjects: 44
Study 22755276 — intervention group
Group type: COMPARATOR
Intervention: Amantadine (relapsers)
Number of subjects: 44
Study 22755276 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma (non-responders)
Number of subjects: 44
Study 22755276 — intervention group
Group type: COMPARATOR
Intervention: Amantadine (non-responders)
Number of subjects: 44
Study 20798393 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (eflornithine)/sulindac
Number of subjects: 228
Study 20798393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 18160923 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture needling
Number of subjects: 39
Study 18160923 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine injection
Number of subjects: 39
Study 16359984 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (200 microg/d)
Number of subjects: 0
Study 16359984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12169967 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 36
Study 12169967 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 36
Study 10670862 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion carotid endarterectomy (ECEA)
Number of subjects: 190
Study 10670862 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carotid endarterectomy with primary closure (CEA)
Number of subjects: 190
Study 10670862 — intervention group
Group type: COMPARATOR
Intervention: Open carotid endarterectomy with patch closure (CEAP)
Number of subjects: 190
Study 7587688 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative parenteral nutritional support (PNS) for 7 days in addition to oral intake
Number of subjects: 0
Study 7587688 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative parenteral nutritional support (PNS)
Number of subjects: 0
Study 2181127 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and disease education
Number of subjects: 53
Study 2181127 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 53
Study 43488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (300 mg daily for 8 weeks)
Number of subjects: 30
Study 43488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol combined with clortalidone
Number of subjects: 30
Study 43488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol combined with phentolamine
Number of subjects: 30
Study 43488 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocking agents alone
Number of subjects: 30
Study 43488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of oxprenolol and clortalidone
Number of subjects: 30
Study 43488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of oxprenolol and phentolamine
Number of subjects: 30
Study 31135570 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐25L hyaluronic acid injectable gel
Number of subjects: 119
Study 31135570 — intervention group
Group type: COMPARATOR
Intervention: Control group (received VYC‐25L 3 months later)
Number of subjects: 119
Study 26938764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone with bupivacaine (8 mg dexamethasone mixed with 18 mL of 0.25% bupivacaine)
Number of subjects: 60
Study 26938764 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with placebo (18 mL of 0.25% bupivacaine and 2 mL of 0.9% saline)
Number of subjects: 60
Study 26938764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone with bupivacaine
Number of subjects: 60
Study 26938764 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with placebo
Number of subjects: 60
Study 25543972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion furosemide
Number of subjects: 427
Study 25543972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 427
Study 25543972 — intervention group
Group type: COMPARATOR
Intervention: High-dose diuretic therapy
Number of subjects: 427
Study 25543972 — intervention group
Group type: COMPARATOR
Intervention: Low-dose diuretic therapy
Number of subjects: 427
Study 25543972 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline log PRA
Number of subjects: 427
Study 25543972 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline log aldosterone
Number of subjects: 427
Study 25543972 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in RAAS biomarkers from baseline to 72 and 96 h
Number of subjects: 427
Study 23841261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcandra glabra (SG) decoction at a daily dose of 20 g
Number of subjects: 100
Study 23841261 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (Control group)
Number of subjects: 100
Study 21070885 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) Reveal XT during 3 Tesla MRI
Number of subjects: 24
Study 19242985 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 46
Study 19242985 — intervention group
Group type: COMPARATOR
Intervention: Anxiety disorder education (ADE)
Number of subjects: 46
Study 17105880 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 25
Study 17105880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15100562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherents to stimulant treatment (n = 41)
Number of subjects: 79
Study 15100562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherents to stimulant treatment (n = 16)
Number of subjects: 79
Study 15100562 — intervention group
Group type: COMPARATOR
Intervention: Medication status at year 2
Number of subjects: 79
Study 15100562 — intervention group
Group type: COMPARATOR
Intervention: Adherence status at year 5
Number of subjects: 79
Study 15100562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of stimulant treatment
Number of subjects: 79
Study 11687919 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/HCTZ 12.5 mg
Number of subjects: 491
Study 11687919 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 491
Study 9219049 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of the listening environment
Number of subjects: 0
Study 8512622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ethanol (LD)
Number of subjects: 21
Study 8512622 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ethanol (HD)
Number of subjects: 21
Study 8512622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 21
Study 2852239 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of Colles' fractures without anesthesia
Number of subjects: 116
Study 2852239 — intervention group
Group type: COMPARATOR
Intervention: Reduction of Colles' fractures with local anesthetic
Number of subjects: 116
Study 29753420 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated strategy
Number of subjects: 268
Study 29753420 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy
Number of subjects: 268
Study 28268619 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual BCI system
Number of subjects: 1
Study 28268619 — intervention group
Group type: COMPARATOR
Intervention: JFK Coma Recovery Scale‐Revised (JFK CRS‐R)
Number of subjects: 1
Study 24593810 — intervention group
Group type: EXPERIMENTAL
Intervention: ß‐tricalcium‐phosphate‐particles with a polylactid coating (ß‐TCP)
Number of subjects: 40
Study 24593810 — intervention group
Group type: EXPERIMENTAL
Intervention: demineralized bovine bone mineral with 10% collagen covered with a collagen matrix (DBBM‐C/CM)
Number of subjects: 40
Study 24593810 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM with 10% collagen covered with an autogenous soft tissue punch graft (DBBM‐C/PG)
Number of subjects: 40
Study 24593810 — intervention group
Group type: COMPARATOR
Intervention: spontaneous healing (control)
Number of subjects: 40
Study 22357026 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual representation of the self exercising
Number of subjects: 30
Study 22357026 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual representation of other person exercising
Number of subjects: 30
Study 22357026 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study 20042841 — intervention group
Group type: EXPERIMENTAL
Intervention: Real patient contact (n = 61)
Number of subjects: 163
Study 20042841 — intervention group
Group type: COMPARATOR
Intervention: Simulated patient contact (n = 102)
Number of subjects: 163
Study 18412270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 308
Study 18412270 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 308
Study 17121049 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM syndrome-typing based therapy (TCM-STBT) combined with cyclosporin
Number of subjects: 58
Study 17121049 — intervention group
Group type: COMPARATOR
Intervention: All-trans-retinoic acid group (control group)
Number of subjects: 58
Study 12505967 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided DLT Broncho-Cath (Group A)
Number of subjects: 64
Study 12505967 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque control blocker Univent (Group B)
Number of subjects: 64
Study 12505967 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided Arndt blocker (Group C)
Number of subjects: 64
Study 11276182 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy interventions with visual biofeedback/forceplate training
Number of subjects: 13
Study 11276182 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy interventions without visual biofeedback/forceplate training (Control)
Number of subjects: 13
Study 9250745 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg for 7 days)
Number of subjects: 685
Study 9250745 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg for 14 days)
Number of subjects: 685
Study 9250745 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (4 x 3 Gy)
Number of subjects: 685
Study 9250745 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (1 x 7 Gy)
Number of subjects: 685
Study 9250745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 685
Study 9250745 — intervention group
Group type: EXPERIMENTAL
Intervention: Single irradiation of 5 Gy
Number of subjects: 685
Study 9250745 — intervention group
Group type: COMPARATOR
Intervention: Matched control series
Number of subjects: 685
Study 8237989 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz standard measles vaccine
Number of subjects: 0
Study 8237989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer Edmonston-Zagreb or Schwarz vaccines
Number of subjects: 0
Study 8237989 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 0
Study 10285532 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM) variables
Number of subjects: 174
Study 10285532 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction measures
Number of subjects: 174
Study 29098470 — intervention group
Group type: COMPARATOR
Intervention: Fish meal (FM) diet
Number of subjects: 0
Study 29098470 — intervention group
Group type: COMPARATOR
Intervention: SBM diet (without Lys or Met supplementation)
Number of subjects: 0
Study 29098470 — intervention group
Group type: EXPERIMENTAL
Intervention: SBM supplement (SBMS) diet (with Lys and Met supplementation)
Number of subjects: 0
Study 28548643 — intervention group
Group type: EXPERIMENTAL
Intervention: HDAC-123
Number of subjects: 568
Study 28548643 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Number of subjects: 568
Study 28548643 — intervention group
Group type: COMPARATOR
Intervention: HDAC-135
Number of subjects: 568
Study 25697851 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 691
Study 25697851 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 691
Study 23600368 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dose of rosuvastatin (40 mg/day)
Number of subjects: 100
Study 23600368 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT)
Number of subjects: 100
Study 23600368 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on statin micronized fenofibrate
Number of subjects: 100
Study 21721969 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Education Questionnaire (PEQ)
Number of subjects: 327
Study 21721969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Questionnaire (IQ)
Number of subjects: 327
Study 21721969 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Service Manager Questionnaire (FSMQ)
Number of subjects: 327
Study 21721969 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Observation (CO)
Number of subjects: 327
Study 21721969 — intervention group
Group type: EXPERIMENTAL
Intervention: School Nutrition Environment Observation (SNEO)
Number of subjects: 327
Study 18978626 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed‐kinetic chain resistance training (CKCRT)
Number of subjects: 14
Study 18978626 — intervention group
Group type: COMPARATOR
Intervention: Open‐kinetic chain resistance training (OKCRT)
Number of subjects: 14
Study 18978626 — intervention group
Group type: EXPERIMENTAL
Intervention: CKCRT
Number of subjects: 14
Study 18978626 — intervention group
Group type: COMPARATOR
Intervention: OKCRT
Number of subjects: 14
Study 16551966 — intervention group
Group type: COMPARATOR
Intervention: Cladribine (2‐CdA) alone
Number of subjects: 508
Study 16551966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine combined with cyclophosphamide (CC)
Number of subjects: 508
Study 16551966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine combined with cyclophosphamide and mitoxantrone (CMC)
Number of subjects: 508
Study 12666705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment (100 mj, 20 pps, 2.0 W, 120 seconds)
Number of subjects: 18
Study 12666705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling (maximum power, 120 seconds)
Number of subjects: 18
Study 12666705 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment (2.0 W, 120 seconds)
Number of subjects: 18
Study 12666705 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Nd:YAG, CO2, and ultrasonic scaling
Number of subjects: 18
Study 10892683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Number of subjects: 30
Study 10892683 — intervention group
Group type: COMPARATOR
Intervention: Videofluoroscopic evaluation of swallowing (VFES)
Number of subjects: 30